Related Experiment Video
Updated: Jun 7, 2025
LAD-Ligation: A Murine Model of Myocardial Infarction
Published on: October 14, 2009
Human platelet lysate combined with mesenchymal stem cells pretreated with platelet lysate improved cardiac function
Hamid Najafipour1, Farzaneh Rostamzadeh2, Seedieh Jafarinejad-Farsangi3
1Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Insights
Human platelet lysate (HPL) and bone marrow mesenchymal stem cells (MSCs) improved heart function after myocardial infarction (MI) in rats. HPL enhanced MSCs
Area of Science:
- Regenerative Medicine
- Cardiovascular Biology
- Stem Cell Therapy
Background:
- Myocardial infarction (MI) is a primary cause of heart failure, disability, and mortality globally.
- Current treatments for MI have limitations in fully restoring cardiac function.
- Investigating novel therapeutic strategies like stem cell-based therapies is crucial for cardiac repair.
Purpose of the Study:
- To evaluate the therapeutic effects of human platelet lysate (HPL) and HPL-pretreated bone marrow mesenchymal stem cells (PMSCs) on myocardial infarction in a rat model.
- To assess the impact of PMSC lysate (PMSC lys) and combined HPL and PMSC treatments.
- To determine the potential of HPL in promoting cardiomyocyte differentiation from PMSCs.
Main Methods:
- Induction of myocardial infarction (MI) in male Wistar rats via LAD ligation.
- Intramyocardial injection of treatments: sham, vehicle (Veh), HPL, PMSCs, PMSC lys, HPL + PMSCs, and HPL + PMSC lys.
- Assessment of cardiac function (SBP, DBP, ±dp/dt max), stem cell characteristics, and expression of CD31, NKX2.5, and cardiac troponin I (cTnI) using physiological monitoring, flow cytometry, immunohistochemistry, and immunofluorescence.
Main Results:
- All treatment groups showed recovery in SBP, DBP, and ±dp/dt max compared to the MI group.
- Enhanced CD31 density was observed in all treated groups, with higher levels in HPL + PMSCs and HPL + PMSC lys groups.
- The HPL + PMSCs group exhibited a greater number of Dil+/NKX2.5+ and Dil+/cTnI+ cells, indicating improved cardiomyocyte differentiation and cardiac regeneration.
Conclusions:
- Human platelet lysate (HPL) and pretreated mesenchymal stem cells (PMSCs) significantly mitigate heart injury and improve cardiac function post-MI.
- Combined HPL and PMSC treatment demonstrates superior efficacy in cardiac repair.
- HPL creates a conducive microenvironment for cardiomyocyte differentiation from PMSCs, highlighting its potential as a therapeutic agent in cardiac regeneration.
Abstract:
Myocardial infarction (MI) is a leading cause of heart failure, disability and mortality worldwide. In this study, the effects of intramyocardial injection of human platelet lysate (HPL), bone marrow mesenchymal stem cells pretreated with HPL (PMSCs), and PMSC lysate (lys), alone and in combination were investigated on MI-induced by LAD ligation in male Wistar rats. The experiment was carried out on sham, vehicle (Veh), HPL, PMSCs, PMSC lysate (PMSC lys), HPL + PMSCs, and HPL + PMSC lys groups. SBP, DBP, and ± dp/dt max were monitored by the PowerLab physiograph. The MSC characteristics and CD31, NKX2.5, and cardiac troponin I (cTnI) contents were determined by flow cytometry, immunohistochemistry, and immunofluorescence, respectively. SBP, DBP, and ± dp/dt max that decreased in the MI group were recovered by HPL, PMSC, PMSC lys, HPL + PMSC, and HPL + PMSC lys treatments. CD31 density was higher in all treated groups compared to the Veh group. CD31 density in the HPL + PMSCs and HPL + PMSC lys groups was higher than in the PMSCs group. The number of Dil+/NKX2.5 + and Dil+/cTnI + cells was higher in the HPL + PMSCs group compared to the PMSCs group. The HPL and PMSCs mitigates heart injuries and cardiac dysfunction after MI. HPL provides an appropriate environment for cardiomyocyte differentiation from PMSCs.
